SEARCH RESULTS FOR:
John Patrick Oroho
EXECUTIVE VICE PRESIDENT AND CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES, LLC
Porzio Life Sciences, LLC (PorzioLS) is a provider of compliance operations products and services for the life sciences industry, and a wholly‐owned subsidiary of the Porzio, Bromberg & Newman, P.C. law firm.
Chris Taylor
PRESIDENT & CEO, GREAT BEAR RESOURCES
Mining in Ontario and Toronto's Global Reach 2020
Great Bear Resources represents a rare instance of a junior that is currently flourishing with significant gold descoveries.
Zafer Toksoz
CHAIRMAN, ARVEN PHARMACEUTICALS
Arven Pharmaceuticals is an R&D based high-tech pharmaceutical company with a focus on research and development, manufacturing and marketing of high-tech pharmaceutical products, including biotech drugs and multi-dose innovative devices for dry powder inhalers.
Enrique Häusermann
PRESIDENT, ASSOCIAZIONE NAZIONALE INDUSTRIE FARMACI GENERICI E BIOSIMILARI (ASSOGENERICI)
Assogenerici is the Italian association that represents the country’s generic and biosimilar pharmaceutical industry.
Don Bubar
PRESIDENT AND CEO, AVALON ADVANCED MATERIALS
Mining in Ontario and Toronto's Global Reach 2020
Avalon Advanced Materials is a mineral development company focused on rare metals and critical minerals for use in clean energy and new technologies.
The Battery Metal Supply Chain
Mining in Ontario and Toronto's Global Reach 2020
North American collaboration in the effort to catch up with China.
Mining in Angola
THE OFFICIAL MINING IN AFRICA COUNTRY INVESTMENT GUIDE (MACIG) 2020
Reforms and privatizations open the door for private-sector investment as Angola looks to diversify its dependency on oil and diamonds.
Hugo Salamanca
PRESIDENT, HIGHSERVICE CORP.
HighService Corp. explains its recent partnership with Metso and speaks of the application of robotics in mining.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
